Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 8, Issue 10, 2010, Pages

[No Author Info available]

Author keywords

blood glucose; blood lipids; body weight; bowel function; glucomannan; glycaemic control; health claims; intestinal transit; konjac mannan; potentially pathogenic organisms; weight management

Indexed keywords

EID: 84889043466     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2010.1798     Document Type: Article

References (23)

1. Birketvedt GS, Shimshi M, Erling T and Florholmen J, 2005. Experiences with three different fiber supplements in weight reduction. Medical Science Monitor, 11, PI5–8.
2. Cairella M and Marchini G, 1995. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. La Clinica Terapeutica, 146, 269–274.
3. Chen HL, Sheu WH, Tai TS, Liaw YP and Chen YC, 2003. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects-a randomized double-blind trial. Journal of the American College of Nutrition, 22, 36–42.
4. Chen HL, Cheng HC, Liu YJ, Liu SY and Wu WT, 2006. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. Nutrition, 22, 1112–1119.
5. Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S and Watzl B, 2004. PASSCLAIM – Gut health and immunity. European Journal of Clinical Nutrition, 43, 18–173.
6. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009. Scientific Opinion on the substantiation of health claims related to glucomannan and maintenance of normal blood cholesterol concentrations (ID 836, 1560) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal, 7(9):1258, 14 pp.
7. Hou YH, Zhang LS, Zhou HM, Wang RS and Zhang YZ, 1990. Influences of refined konjac meal on the levels of tissue lipids and the absorption of four minerals in rats. Biomedical and Environmental Sciences, 3, 306–314.
8. Katsuraya K, Okuyama K, Hatanaka K, Oshima R, Sato T and Matsuzaki K, 2003. Constitution of konjac glucomannan: chemical analysis and 13C NMR spectroscopy. Carbohydrate Polymers, 53, 183–189.
9. Keithley J and Swanson B, 2005. Glucomannan and obesity: a critical review. Alternative Therapies in Health and Medicine, 11, 30–34.
10. Loening-Baucke V, Miele E and Staiano A, 2004. Fiber (Glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics, 113, e259–e264.
11. Magnati G, Arsenio L, Bodria P, Lateana M and Strata A, 1984. [Dietary fiber and OGTT: blood sugar variations after administration of a new purified glucomannane]. Acta Bio-Medica de l'Ateneo Parmense, 55, 5–14.
12. Marzio L, Del Bianco R, Donne MD, Pieramico O and Cuccurullo F, 1989. Mouth-to-cecum transit time in patients affected by chronic constipation: effect of glucomannan. American Journal of Gastroenterology, 84, 888–891.
13. Passaretti S, Franzoni M, Comin U, Donzelli R, Rocca F, Colombo E, Ferrara A, Dinelli M, Prada A and Curzio M, 1991. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Italian Journal of Gastroenterology, 23, 421–425.
14. Staiano A, Simeone D, Del Giudice E, Miele E, Tozzi A and Toraldo C, 2000. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. Journal of Pediatrics, 136, 41–45.
15. Venn BJ and Green TJ, 2007. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. European Journal of Clinical Nutrition, 61, 122–131.
16. Vido L, Facchin P, Antonello I, Gobber D and Rigon F, 1993. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Pädiatrie und Pädologie, 28, 133–136.
17. Vita PM, Restelli A, Caspani P and Klinger R, 1992. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Medica, 83, 135–139.
18. Vorster HH, Kruger HS, Frylink S, Botha BJ, Lombaard WA and De Jager J, 1985. Physiological effects of the dietary fibre component konjac glucomannan in rats and baboons. Journal of Plant Foods, 6, 263–274.
19. Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA and Bruce-Thompson C, 1999. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care, 22, 913–919.
20. Vuksan V, Sievenpiper JL, Owen R, Swilley JA, Spadafora P, Jenkins DJ, Vidgen E, Brighenti F, Josse RG, Leiter LA, Xu Z and Novokmet R, 2000. Beneficial effects of viscous dietary fiber from konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care, 23, 9–14.
21. Vuksan V, Sievenpiper JL, Xu Z, Wong EY, Jenkins AL, Beljan-Zdravkovic U, Leiter LA, Josse RG and Stavro MP, 2001. Konjac-mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. Journal of the American College of Nutrition, 20, 370S–380S.
22. Walsh DE, Yaghoubian V and Behforooz A, 1984. Effect of glucomannan on obese patients: a clinical study. International Journal of Obesity, 8, 289–293.
23. Wood RJ, Fernandez ML, Sharman MJ, Silvestre R, Greene CM, Zern TL, Shrestha S, Judelson DA, Gomez AL, Kraemer WJ and Volek JS, 2007. Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism, 56, 58–67.